GlobeNewswire

ObsEva SA to present at The International Society of Gynecological Endocrinology 19th World Congress – virtual edition, December 2-5, 2020

Share


Geneva, Switzerland and Boston, MA – December 1, 2020 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health today announced that Ernest Loumaye, MD, PhD, co-founder and member of the Board of Directors, will give a presentation at the ISGE (International Society of Gynecological Endocrinology) 19th World Congress Virtual Edition, December 2-5, 2020.

Dr Loumaye’s presentation will take place during the symposium available on demand on Friday December 4th from 08:00 am GMT and accessible for 4 months. The link to the Congress and sessions will be available under “Events Calendar” in the investors section of ObsEva’s website at www.ObsEva.com

Symposium:      IVF AND PREGNANCY: Recent development in IVF

Date:                Friday December 4th

Title:                The use of a novel oxytocin receptor antagonist, nolasiban, prior to embryo transfer: does it help?

About ObsEva

ObsEva is a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids, preterm labor, and improving ET outcomes following IVF. ObsEva is listed on the Nasdaq Global Select Market and is trading under the ticker symbol "OBSV" and on the SIX Swiss Exchange where it is trading under the ticker symbol “OBSN”. For more information, please visit www.ObsEva.com.

About Nolasiban

Nolasiban (previously known as OBE001), is an oral oxytocin receptor antagonist which was licensed from Merck KGaA, Darmstadt, Germany, in 2013. ObsEva retains worldwide, exclusive, commercial rights (ex China).

Cautionary Note Regarding Forward Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as "believe", "expect", "may", "plan," "potential," "will," and similar expressions, and are based on ObsEva’s current beliefs and expectations. These forward-looking statements include expectations regarding the clinical development of ObsEva’s product candidates. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials, clinical development and related interactions with regulators, , ObsEva’s reliance on third parties over which it may not always have full control, the impact of the novel coronavirus outbreak, and other risks and uncertainties that are described in the Risk Factors section of ObsEva’s Annual Report on Form 20-F for the year ended December 31, 2019, the Risk Factors disclosed in ObsEva’s Report on Form 6-K filed with the Securities and Exchange Commission (SEC) on November 5, 2020 and other filings ObsEva makes with the SEC. These documents are available on the Investors page of ObsEva’s website at http://www.obseva.com. Any forward-looking statements speak only as of the date of this press release and are based on information available to ObsEva as of the date of this release, and ObsEva assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.

For further information, please contact:

CEO Office contact
Shauna Dillon
Shauna.dillon@obseva.ch
+41 22 552 1550

Attachment


About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Corr: SpareBank 1 SMN: Presentation of 4th Quarter 2020 accounts22.1.2021 13:23:24 CETPress release

SpareBank 1 SMN is presenting 4th quarter 2020 financial results. Time: Friday 5 February at 08:00 AM CET Place: Webinar Please register by 4 February on the link below: http://epost.sparebank1.no/public/event/RegistrationForm/42445A4B79474450427340 The presentation will be held in Norwegian by group CEO Jan-Frode Janson and CFO Kjell Fordal. We will also host a Global Investor Webinar in English on the same day at 3:15 PM CET. Please register by 4 February on the following link: http://epost.sparebank1.no/public/event/RegistrationForm/42445A4B794041504B7040 Questions to the management in relation to both presentations can be sent to ir@smn.no. The results will be published on 5 February at 7:00 AM CET. This information is subject of the disclosure requirements acc. to §5-12 vphl (Norwegian Securities Trading Act)

Korr: SpareBank 1 SMN: Invitasjon til resultatpresentasjon, 4. kvartal 202022.1.2021 13:23:24 CETPressemelding

SpareBank 1 SMN inviterer til presentasjon av resultatene for 4. kvartal 2020. Tid: Fredag, 5. februar, kl. 08:00 Sted: Webinar Påmelding innen 4. februar via følgende link: http://epost.sparebank1.no/public/event/RegistrationForm/42445A4B79474450427340 Presentasjonen holdes av konsernsjef Jan-Frode Janson og finansdirektør Kjell Fordal. Det vil også bli holdt et webinar på engelsk samme dag klokken 15:15. Påmelding til den engelske presentasjonen innen 4. februar kan gjøres her: http://epost.sparebank1.no/public/event/RegistrationForm/42445A4B794041504B7040 Spørsmål til begge presentasjoner kan sendes til ir@smn.no. Resultatet publiseres 5. februar klokken 07:00 Denne opplysningen er informasjonspliktig etter verdipapirhandelloven §5-12

PCI Biotech to present at RNA Therapeutics Virtual Conference22.1.2021 12:04:15 CETPress release

Oslo (Norway), 22 January 2021 – PCI Biotech (OSE: PCIB), a clinical-stage biopharma company developing innovative therapeutics that address significant unmet medical needs in cancer today announced that it will present at the 12th Annual RNA Therapeutics Virtual Conference, a UK based online event taking place February 10-11, 2021. The 2021 conference is set to explore the latest developments in RNA delivery agents and RNA-based therapeutics with the latest case studies on advanced mRNA technologies, oligonucleotide delivery, therapeutic applications and future trends and innovations. PCI Biotech is also a sponsor of the event. On Wednesday, February 10, 2021 at 13:10pm (CET), Dr. Anders Høgset, CSO, will present an overview of PCI Biotech’s proprietary platform technology, focusing on the delivery of RNA molecules, including the most recent data on the use of the fimaNAc delivery technology in the exciting field of RNA based therapies. The presentation slides will be made available t

SpareBank 1 SMN: Invitasjon til resultatpresentasjon, 4. kvartal 202022.1.2021 10:47:43 CETPressemelding

SpareBank 1 SMN inviterer til presentasjon av resultatene for 4. kvartal 2020. Tid: Fredag, 5. februar, kl. 08:00 Sted: Webinar Påmelding innen 4. februar via følgende link: http://epost.sparebank1.no/public/event/RegistrationForm/42445A4B79474450427340 Presentasjonen holdes av konsernsjef Jan-Frode Janson og finansdirektør Kjell Fordal. Det vil også bli holdt et webinar på engelsk samme dag klokken 15:15. Påmelding til den engelske presentasjonen innen 4. februar kan gjøres her: http://epost.sparebank1.no/public/event/RegistrationForm/42445A4B794041504B7040 Spørsmål til begge presentasjoner kan sendes til ir@smn.no. Resultatet publiseres 5. februar klokken 07:00 Denne opplysningen er informasjonspliktig etter verdipapirhandelloven §5-12

SpareBank 1 SMN: Presentation of 4th Quarter 2020 accounts22.1.2021 10:47:43 CETPress release

SpareBank 1 SMN is presenting 4th quarter 2020 financial results. Time: Friday 5 February at 08:00 AM CET Place: Webinar Please register by 4 February on the link below: http://epost.sparebank1.no/public/event/RegistrationForm/42445A4B79474450427340 The presentation will be held in Norwegian by group CEO Jan-Frode Janson and CFO Kjell Fordal. We will also host a Global Investor Webinar in English on the same day at 3:15 PM CET. Please register by 4 February on the following link: http://epost.sparebank1.no/public/event/RegistrationForm/42445A4B794041504B7040 Questions to the management in relation to both presentations can be sent to ir@smn.no. The results will be published on 5 February at 7:00 AM CET. This information is subject of the disclosure requirements acc. to §5-12 vphl (Norwegian Securities Trading Act)

RESULT OF RIKSBANK REVERSED AUCTIONS SEK GOVERNMENT BONDS22.1.2021 10:07:00 CETPress release

Auction date2021-01-22Loan3111Coupon0.125 %ISIN-codeSE0007045745Maturity2032-06-01Tendered volume, SEK mln500 +/- 250Volume offered, SEK mln1,674Volume bought, SEK mln500Number of bids14Number of accepted bids6Average yield-1.592Lowest accepted yield-1.598Highest yield-1.585% accepted at lowest yield 33.33 Auction date2021-01-22Loan3112Coupon0.125 %ISIN-codeSE0008014062Maturity2026-06-01Tendered volume, SEK mln500 +/- 250Volume offered, SEK mln1,450Volume bought, SEK mln500Number of bids10Number of accepted bids3Average yield-1.727Lowest accepted yield-1.731Highest yield-1.719% accepted at lowest yield 100.00